Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC

Chinese Academy of Medical Sciences & Peking Union Medical College logo

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase

Unknown
Phase 3

Conditions

Lung Neoplasms
Carcinoma, Small Cell

Treatments

Radiation: hypofractionated concurrent chemoradiotherapy
Radiation: conventionally fractionated concurrent chemoradiotherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT02688036
CH-L-045/2

Details and patient eligibility

About

The purpose of this study is to determine whether hypofractionated concurrent chemo-radiotherapy has the same efficiency as conventionally fractionated concurrent chemo-radiotherapy in Limited Disease Small Cell Lung Cancer.

Full description

For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm. While 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm. Both survival and toxicity of the two arms will be observed and compared.

Enrollment

860 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18~70 years old, ECOG 0-2
  • patients with histologically or cytologically proved small cell lung cancer
  • Limited disease (LD), was characterized by tumors confined to one hemithorax. It may include ipsilateral hilar, both mediastinum and both supraclavicular nodes. Metastatic lymph nodes were defined as lymph nodes with short diameter of more than 1cm or FDG uptake in PET. The thickness of pleural effusion was less than 1cm unless malignant pleural effusion was cytologically proved. In a word, stage I-IIIB excluding the patients with lung metastases should be defined as LD according to AJCC cancer staging 7th edition.
  • No progression after 2 cycles of chemotherapy with EP.
  • No prior history of anti-tumor treatment.
  • No severe internal diseases and no organ dysfunction
  • Written informed consent provided and

Exclusion criteria

  • Malignant tumors of other sites. Non melanoma skin cancer and Cervical carcinoma in situ were not included if curable.
  • Active heart disease or acute myocardial infarction happen in six months.
  • Psychiatric history.
  • Pregnant woman or woman need to breast feed or woman with positive chorionic gonadotrophin (HCG)
  • Uncontrolled diabetes or hypertension
  • Interstitial pneumonia or Active pulmonary fibrosis
  • Acute bacterial or fungal infection
  • Oral or intravenous use of steroids

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

860 participants in 2 patient groups

hypofractionated CRT
Experimental group
Description:
hypofractionated concurrent chemoradiotherapy
Treatment:
Radiation: hypofractionated concurrent chemoradiotherapy
conventionally fractionated CRT
Active Comparator group
Description:
conventionally fractionated concurrent chemoradiotherapy
Treatment:
Radiation: conventionally fractionated concurrent chemoradiotherapy

Trial contacts and locations

1

Loading...

Central trial contact

LuHua Wang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems